Lyra Therapeutics (LYRA) Non-Current Deffered Revenue (2021 - 2025)
Quarterly Non-Current Deffered Revenue changed 0.0% to $11.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.9 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $11.9 million for FY2025, 0.0% changed from the prior year.
Lyra Therapeutics' Non-Current Deffered Revenue history spans 5 years, with the latest figure at $11.9 million for Q4 2025.
- Non-Current Deffered Revenue came in at $11.9 million for Q4 2025, roughly flat from $11.9 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $14.1 million in Q4 2022 to a low of $1.9 million in Q4 2021.
- The 5-year median for Non-Current Deffered Revenue is $11.9 million (2024), against an average of $10.7 million.
- Year-over-year, Non-Current Deffered Revenue soared 630.89% in 2022 and then decreased 13.79% in 2023.
- Lyra Therapeutics' Non-Current Deffered Revenue stood at $1.9 million in 2021, then skyrocketed by 630.89% to $14.1 million in 2022, then dropped by 13.79% to $12.1 million in 2023, then fell by 2.26% to $11.9 million in 2024, then changed by 0.0% to $11.9 million in 2025.
- Per Business Quant, the three most recent readings for LYRA's Non-Current Deffered Revenue are $11.9 million (Q4 2025), $11.9 million (Q3 2025), and $11.9 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 225.10 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Lyra Therapeutics | - | - | - | 11.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.86 Mn |
| Sep 30, 2025 | 11.86 Mn |
| Jun 30, 2025 | 11.86 Mn |
| Mar 31, 2025 | 11.86 Mn |
| Dec 31, 2024 | 11.86 Mn |
| Sep 30, 2024 | 11.86 Mn |
| Jun 30, 2024 | 11.85 Mn |
| Mar 31, 2024 | 11.94 Mn |
| Dec 31, 2023 | 12.14 Mn |
| Sep 30, 2023 | 12.21 Mn |
| Jun 30, 2023 | 12.99 Mn |
| Mar 31, 2023 | 13.43 Mn |
| Dec 31, 2022 | 14.08 Mn |
| Sep 30, 2022 | 12.63 Mn |
| Jun 30, 2022 | 13.18 Mn |
| Mar 31, 2022 | 2.02 Mn |
| Dec 31, 2021 | 1.93 Mn |
| Sep 30, 2021 | 2.15 Mn |